Ionis Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Ionis Pharmaceuticals Inc in one report.

  • Save hours of research time and resources with
    our up-to-date Ionis Pharmaceuticals Inc Strategy Report

  • Understand Ionis Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Ionis Pharmaceuticals Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Ionis Pharmaceuticals Inc (Ionis), formerly ISIS Pharmaceuticals Inc, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.

Gain a 360-degree view of Ionis Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Ionis Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America

Address 2855 Gazelle Court, Carlsbad, California, 92010


Telephone 1 760 9319200

No of Employees 927

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange IONS (NASD)

Revenue (2022) $787.6M 34.1% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ -35.8% (2022 vs 2021)

Market Cap* $5.5B

Net Profit Margin (2022) XYZ -1.3% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Ionis Pharmaceuticals Inc premium industry data and analytics

210+

Clinical Trials

Determine Ionis Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

200+

Catalyst Calendar

Proactively evaluate Ionis Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

190+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Ionis Pharmaceuticals Inc’s relevant decision makers and contact details.

130+

Pipeline Drugs

Identify which of Ionis Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

50+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

10+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Ionis Pharmaceuticals Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Marketed Drugs

Understand Ionis Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Ionis Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Nusinersen - Spinal Muscular Atrophy -
Inotersen - Polyneuropathy Spinraza
Volanesorsen - Familial Chylomicronemia Syndrome Tegsedi
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Ionis Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Ionis Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In August, the company signed a collaboration and license agreement with Novartis for the discovery, development, and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease.
2023 Contracts/Agreements In July, the company entered into a multi-disease area collaboration with Scipher Medicine for advancing, developing and commercializing oligonucleotide therapies directed to targets discovered by Scipher’s Spectra platform.
2023 Contracts/Agreements In July, the company expanded its partnership with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Ionis Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Intercept Pharmaceuticals Inc Arrowhead Pharmaceuticals Inc Enzo Biochem Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Carlsbad Cambridge Morristown Pasadena Farmingdale
State/Province California Massachusetts New Jersey California New York
No. of Employees 927 2,100 341 525 179
Entity Type Public Public Private Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Joseph Loscalzo, M.D., Ph.D. Chairman Executive Board 2021 71
Brett P. Monia, Ph.D. Chief Executive Officer; Director Executive Board 2020 61
Elizabeth L. Hougen Chief Financial Officer; Executive Vice President - Finance Senior Management 2013 61
Darren Gonzales Chief Accounting Officer; Senior Vice President Senior Management - -
Patrick R. O’Neil Chief Legal Officer; General Counsel; Secretary Senior Management 2021 49
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Ionis Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Ionis Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer